Cargando…
Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review
The current case study aimed to explore the efficacy of a low-dose bevacizumab regimen in inhibiting tumor growth and minimizing adverse effects. A 55-year-old man with neurofibromatosis type 2 (NF2) suffered bilateral vestibular schwannomas (VS) measuring 5.25 and 2.54 cm(3) on the left and right,...
Autores principales: | LIU, PENGFEI, YAO, QINGYU, LI, NA, LIU, YONGLIANG, WANG, YUGUO, LI, MENG, LI, ZEFU, LI, JIANMIN, LI, GANG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840682/ https://www.ncbi.nlm.nih.gov/pubmed/27123050 http://dx.doi.org/10.3892/ol.2016.4347 |
Ejemplares similares
-
Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
por: FUJII, Masazumi, et al.
Publicado: (2020) -
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
por: Webb, M J, et al.
Publicado: (2023) -
New developments in neurofibromatosis type 2 and vestibular schwannoma
por: Ren, Yin, et al.
Publicado: (2020) -
Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients
por: Gugel, Isabel, et al.
Publicado: (2019) -
Coexistent vestibular schwannoma and meningioma in a patient without neurofibromatosis: A case report and review of literature
por: Zhao, Li-Yan, et al.
Publicado: (2021)